<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03588598</url>
  </required_header>
  <id_info>
    <org_study_id>SHC014-I-01</org_study_id>
    <nct_id>NCT03588598</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Indolent B-Cell Hematologic Malignancies</brief_title>
  <official_title>A Phase I Dose Escalation Study to Investigate the Safety, Tolerability, and Pharmacokinetics of SHC014748M in Patients With Relapsed or Refractory Indolent B-Cell Hematologic Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing Sanhome Pharmaceutical, Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing Sanhome Pharmaceutical, Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics of
      SHC014748M in patients with relapsed or refractory indolent B-cell hematologic malignancies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I, sequential dose escalation followed by cohort expansion study of
      SHC014748M, an oral inhibitor of PI3K delta, in patients with relapsed or refractory indolent
      B-cell hematologic malignancies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 7, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity (DLT)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Plasma Concentration（Tmax）</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life Time(t1/2)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration Versus Time Curve (AUC)</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lymph Node Response (LNR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Chronic Lymphocytic Leukemia (CLL)</condition>
  <condition>Small Lymphocytic Lymphoma (SLL)</condition>
  <condition>B-Cell Non-Hodgkin Lymphomas(NHL)</condition>
  <arm_group>
    <arm_group_label>SHC014748M treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SHC014748M capsule， 50, 100, 150, 200, 250 mg, QD, 28 days for each cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SHC014748M</intervention_name>
    <description>a selective PI3Kδ inhibitor</description>
    <arm_group_label>SHC014748M treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1.18- 75 years of age.

        2.Histologically or cytologically confirmed diagnosis of relapsed or refractory indolent
        B-cell hematologic malignancies, including but not limited to CLL / SLL, FL (grade 1, 2 or
        3a), or MZL.

        3.Patients have received at least 1 prior regimen (at least 2 cycles).

        4.Eastern Cooperative Oncology Group (ECOG) performance score of 0-2.

        5.Life expectancy ≥ 3 months.

        6.Patients have at least 1 measurable lesion that measures ≥1.5 cm in a single dimension as
        assessed by CT or MRI.

        7.Adequate organ function, as defined by the following values: ANC≥1.0×10^9/L；
        PLT≥50×10^9/L； Hb≥80 g/L； TBIL≤1.5×ULN； ALT and AST≤2.5×ULN； BUN and Cr≤1.5×ULN； LVEF≥50%；
        QTcF &lt;450 ms for male, QTcF &lt;470 ms for female；

        8.Men and women of childbearing potential are willing to employ an effective method of
        contraception for the entire duration of study and 6 months after the last dose, and female
        subjects of childbearing potential have a negative pregnancy test at baseline.

        9.Subjects did not participate in other clinical trials within 3 months prior to study
        entry.

        Exclusion Criteria:

          1. Disease progression after previous treatment with any PI3Kδ inhibitors.

          2. Had any other anti-tumor treatment within 4 weeks prior to screening (including
             radiotherapy, chemotherapy, hormone therapy, surgery or targeted therapy).

          3. Evidence of central nervous system involvement of the malignancy.

          4. Evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension, active bleeding diatheses, uncontrolled pleural effusion and ascites,
             uncontrolled diabetes, non-infectious pneumonia, and any other severe cardiovascular,
             respiratory, nervous and mental diseases.

          5. Any of the severe heart diseases, including New York Heart Association (NYHA) Class II
             or greater heart failure, arrhythmias requiring medical treatment, and history of
             myocardial infarction or unstable angina within 6 months prior to screening.

          6. Require any concomitant medication known to prolong the QT interval during the study.

          7. Evidence of active bacterial, fungal, or viral infection.

          8. Active infection with hepatitis B virus (HBV) (HBsAg positive, or HBsAg negative and
             HBV-DNA positive), hepatitis C virus (HCV), or human immunodeficiency virus (HIV).

          9. Use of high-dose glucocorticoids (eg, ≥20 mg/day prednisone) or other
             immunosuppressants within 4 weeks prior to study entry.

         10. Concomitant use of any strong inhibitors or inducers of CYP3A4.

         11. Use of G-CSF or blood transfusion within 7 days before the hematology test at
             screening.

         12. Prior autologous hematopoietic stem cell transplantation within 6 months prior to
             treatment initiation.

         13. History of prior allogeneic hematopoietic stem cell transplantation.

         14. Major surgery within 4 weeks prior to treatment initiation.

         15. History of a non-lymphoma malignancy in the past five years except for the following:
             adequately treated cervical carcinoma in situ, local basal cell or squamous cell
             carcinoma of the skin.

         16. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the drug or previous significant bowel resection that would preclude adequate
             absorption of the study drug.

         17. History of hypersensitivity to drugs similar to the study drug or inactive excipients
             of the study drug.

         18. Women who are breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jianyong Li, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital with Nanjing Medical University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jie Jin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The First Affiliated Hospital, Zhejiang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Guo</last_name>
    <phone>+86025-81066427</phone>
    <email>guoweiyf@sanhome.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaodan Lyu</last_name>
    <phone>+86025-81066469</phone>
    <email>lvxd@sanhome.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First Affiliated Hospital with Nanjing Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianyong Li, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jie Jin, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>June 28, 2018</study_first_submitted>
  <study_first_submitted_qc>July 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 17, 2018</study_first_posted>
  <last_update_submitted>April 27, 2019</last_update_submitted>
  <last_update_submitted_qc>April 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CLL</keyword>
  <keyword>SLL</keyword>
  <keyword>NHL</keyword>
  <keyword>SHC014748M</keyword>
  <keyword>Phosphatidylinositol 3-kinase (PI3K)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

